Clinical trial · Interventional
Trial of Iressa in Prostate Cancer Patients
An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy
NCT00265070CI-TRIAL-00009301completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary objective of the trial is to evaluate the activity of oral ZD1839 (250 mg once daily administered continuously) in subjects with early biochemical failure post prostatectomy by estimating the PSA response rate
Secondary outcomes (4)
- measure
- To estimate the duration of PSA response
- measure
- To estimate the partial PSA response rate
- measure
- To estimate the change in the ratio of free PSA : total PSA at 6 and 12 months compared with baseline
- measure
- To investigate the change in PSA levels after discontinuation of ZD1839
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Removal of prostate for prostate cancer * Raised level of prostate specific antigen (PSA) post-surgery * Can have received some radiation therapy Exclusion Criteria: * Any after surgery male hormone blocking therapy. * Low white blood cell count * Abnormal liver function test
References
Publications (0)
Data not yet available
No reference posted for this study.